Edwards Lifesciences CORP Form 4 insider transactions

Director Ramona Sequeira acquired 3,528 shares of Edwards Lifesciences Corp stock through a restricted stock unit grant.

Director Steven R. Loranger reports receiving restricted stock units and a restricted stock award from Edwards Lifesciences on May 9, 2025.

Director Paul A. Laviolette reports acquisition of 3,528 restricted stock units in Edwards Lifesciences Corp.

Director Leslie Stone Heisz reports acquisition of 3,528 restricted stock units in Edwards Lifesciences Corp.

Director Kieran Gallahue reported the acquisition of common stock through restricted stock units and awards granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.

David T. Feinberg, a director at Edwards Lifesciences, acquired 3,528 shares of common stock through a restricted stock unit grant.

Director Leslie C. Davis reports acquisition of 3,528 restricted stock units in Edwards Lifesciences Corp.

Annette Bruls, CVP of EMEACLA at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports acquisition and disposal of company stock and stock options.

Andrew Dahl, SVP, Corporate Controller at Edwards Lifesciences, reports the acquisition of restricted stock units and employee stock options.

Wayne Markowitz, GM & SVP of Surgical at Edwards Lifesciences, reports stock sales, option grants, and restricted stock unit awards.

Daveen Chopra, CVP at Edwards Lifesciences, reports acquisition and disposal of company stock and stock options.

Scott Ullem, CFO of Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

CEO Bernard Zovighian reports transactions involving Edwards Lifesciences Corp stock, including acquisitions, disposals, and grants of stock options and restricted stock units.

Larry L. Wood, Global President of TAVR & Surg at Edwards Lifesciences, reports acquisition and disposal of common stock and derivative securities.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

CEO Bernard Zovighian reports transactions involving Edwards Lifesciences Corp stock, including acquisitions, disposals, and option exercises, pursuant to a pre-arranged trading plan.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, disposed of shares to cover tax obligations arising from equity awards.

Larry L. Wood, Global President TAVR & Surg at Edwards Lifesciences, reports transactions involving common stock, including disposals to cover tax obligations and acquisitions through the Employee Stock Purchase Plan.

Daveen Chopra, a CVP at Edwards Lifesciences, reported the disposal of common stock on May 3rd and 4th, 2025, to cover tax obligations.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, reported disposing of shares to cover tax obligations arising from vesting restricted stock units.

CVP and Chief Financial Officer of Edwards Lifesciences, Scott B. Ullem, reports changes in beneficial ownership of company stock due to tax withholding.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the acquisition and disposal of company stock under a pre-arranged trading plan.

Scott Ullem, CFO of Edwards Lifesciences, exercised stock options and sold shares on March 26, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

CEO Bernard Zovighian reports exercising stock options and selling shares of Edwards Lifesciences common stock under a pre-arranged trading plan.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the acquisition and disposal of common stock and the exercise of employee stock options on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Scott B. Ullem, CFO of Edwards Lifesciences, exercised stock options and sold shares on February 28, 2025, according to a Form 4 filing with the SEC.

Andrew M. Dahl, SVP, Corporate Controller of Edwards Lifesciences, reports a disposition of 176 shares of common stock on February 22, 2025, at a price of $73.3 per share.